Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10714962 | 0.81 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9085540 | 0.81 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8907488 | 0.78 | ALDH1A1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16048996 | 0.78 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9412307 | 0.73 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16079405 | 0.73 | ADORA1 (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13369154 | 0.71 | ALDH1A1 (0.69) | SMN1; SMN2TDP1ALDH1A1HPGDMAPT | |
| SCHEMBL13359463 | 0.70 | GSK3B (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14214645 | 0.69 | BRD4 (0.41) | ALDH1A1HPGDMAPTKDM4EMAPK1 | |
| SCHEMBL5788019 | 0.69 | CA12 (1.00) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067898-B1 | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GLP1R, GCGR | CA12 4335/4885CA1 4723/4885CA2 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.